Citigroup’s Fractyl Health GUTS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.24K Buy
+7,852
New +$5.59K ﹤0.01% 5291
2026
Q1
Sell
-35,076
Closed -$77.2K 6471
2025
Q4
$77.2K Buy
35,076
+34,859
+16,064% +$56.1K ﹤0.01% 4429
2025
Q3
$345 Buy
217
+3
+1% +$4 ﹤0.01% 5733
2025
Q2
$347 Sell
214
-23,800
-99% -$38.5K ﹤0.01% 5460
2025
Q1
$28.6K Sell
24,014
-2,879
-11% -$4.6K ﹤0.01% 5017
2024
Q4
$55.4K Buy
26,893
+2,199
+9% +$5.12K ﹤0.01% 5059
2024
Q3
$62.5K Buy
24,694
+23,041
+1,394% +$75.2K ﹤0.01% 4950
2024
Q2
$7.06K Sell
1,653
-46,077
-97% -$296K ﹤0.01% 5213
2024
Q1
$353K Buy
+47,730
New +$402K ﹤0.01% 3754

Other funds holding GUTS

Citigroup's GUTS Position: Q2 2026 in Review

Citigroup opened a new position in Fractyl Health (GUTS) in Q2 2026: 7,852 shares worth $6.24K. The stake represents ﹤0.01% of the portfolio and ranks #5291 among its holdings. This is a return to the name: Citigroup previously reported a position in GUTS as recently as Q4 2025.

Citigroup first reported a position in GUTS in Q1 2024 and has held it in 9 quarters since. The position peaked at $353K in Q1 2024. 77 funds tracked by Wall St. Rank hold GUTS as of Q2 2026.

  • Citigroup held 7,852 shares of Fractyl Health worth $6.24K as of Q2 2026.
  • Fractyl Health was a new Citigroup position in Q2 2026.
  • Fractyl Health made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5291 holding.
  • Citigroup first reported a position in Fractyl Health in Q1 2024 and has held it in 9 quarters since.
  • Citigroup's Fractyl Health position peaked at $353K in Q1 2024.
  • 77 funds tracked by Wall St. Rank held Fractyl Health as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.